In Germany, with the introduction of the Pharmaceutical Market Restructuring Act (AMNOG) in January 1st2011, pricing and reimbursement decisions for new drugs have been driven by the early benefit assessment (EBA). G-BA can decide to set or not a time limitation to the decision. The Objectives of this study were, first, to review the number of time-limited decisions over time and second, to identify drivers of these decisions.